X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

GOSS

Closed

Gossamer Bio Inc

1.25
+0.02 (+1.63%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 1.23
Day's Range: 1.195 - 1.33
Send
When Written:
 
1.175
Gossamer Bio Inc is a clinical-stage biopharmaceutical company that develops and commercializes immunology-based therapies to treat patients with life-threatening diseases. The company was founded in 2015 and is headquartered in San Diego, California.

Gossamer Bio's pipeline includes several drug candidates in various stages of development, targeting diseases such as asthma, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (IBD). The company's lead product candidate, GB001, is an oral small molecule antagonist of prostaglandin D2 receptor 2 (DP2) that is being developed for the treatment of moderate-to-severe eosinophilic asthma.

Gossamer Bio has collaborations with several pharmaceutical companies, including Pfizer and Merck, to develop and commercialize its drug candidates. The company went public in 2019 and is listed on the NASDAQ stock exchange under the ticker symbol "GOSS."

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X